A Study of Ridaforolimus in Non-Small Cell Lung Cancer (NSCLC) Patients With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutations (MK-8669-021 AM1)

Inclusion Criteria:

• Patient has histologically confirmed stage IIIB/IV non-small cell lung cancer
• Patient has a documented mutation of the KRAS gene
• Patient has evidence of disease progression following 1 but no more than 3 prior chemotherapy regimens
• A minimum of 4 weeks has passed since the most recent anti-cancer treatment
• Women of childbearing potential must have a negative pregnancy test prior to start of therapy and must use an approved contraceptive method for the duration of the study
• Patient has adequate organ function
• Patient has performance status of <=2 on Eastern Cooperative Oncology Group (ECOG) performance scale
• Patient is >=18 years of age

Exclusion Criteria:

• Patient has received more than 2 prior chemotherapy regimens for the treatment lung cancer
• Patient is known to have active brain metastases
• Patient is currently participating or has participated in an investigational drug study within 30 days
• Patient is known to be Human Immunodeficiency Virus (HIV) positive or has a known history of Hepatitis B or C
• Patient has an active infection requiring prescribed intervention
• Patient has newly diagnosed or un-controlled Type 1 or 2 diabetes